Business Wire

Carbios Accelerates Its Enzyme Optimization With Screening Capabilities for Millions of Enzymes in a Day

18.4.2023 07:45:00 EEST | Business Wire | Press release

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230417005658/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Microfluidics accelerates enzymatic screening process (Photo: Carbios)

Carbios (Euronext Growth Paris: ALCRB) (Paris:ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and textiles, has accelerated its enzyme screening process with a microfluidic technology developed in partnership with the Paul Pascal Research Centre (a joint research unit of the CNRS and the University of Bordeaux, which specializes in microfluidics). This cutting-edge technology enables the screening of millions of enzymes in just one day, speeding up the process to optimize enzymes breaking down PET. This competitive advantage enables Carbios to reduce the time between the R&D phase and the production of its proprietary enzymes, and therefore to develop concrete solutions to plastic pollution even faster.

"Since having applied microfluidics to our screening process more than a year ago, we have analyzed millions of enzymes, which would have taken years beforehand," explains Prof. Alain Marty, Chief Scientific Officer at Carbios. "This technology gives access to a large variety of enzymes in record time. Microfluidics has enabled us to optimize the enzyme presented in 2020 in the journal Nature, and it is this optimized enzyme that will be used in our first industrial reference unit in 2025."

"Microfluidics is already widely used in medical diagnostics to analyze biological samples. When Carbios approached us to use it for new industrial applications, this was a first," said Jean-Christophe Baret, Professor at the University of Bordeaux and team leader at the Paul Pascal Research Center hosted by the CNRS. "We are very pleased to develop new methods using the power of microfluidics for an environmental cause such as the reduction of plastic pollution."

Microfluidics: the science of droplets

Microfluidics allows the production of devices handling very small amounts of liquid. Each droplet generated can be considered as an independent microreactor having a volume in the picoliter range (10-12 liters) and containing a particular enzyme whose PET depolymerization activity will be screened. These droplets move through analysis units the size of a microchip allowing ultra-high throughput screening of 150 enzymes per second.

Previously, conventional robotic systems allowed screening in microplate format with a volume in the milliliter range (10-3 liters) and with rates of around one enzyme per minute.

The use of microfluidics to screen for more efficient or new enzymes will become widely adopted in the coming years, therefore accelerating the development of bioprocessing. Currently used by Carbios for the development of its PET depolymerization process, microfluidics should be used to accelerate the development of new enzymes for other types of plastic such as polyamide.

Carbios researchers specialized in microfluidics

Microfluidic processes require special expertise. At present, two researchers at Carbios are dedicated to microfluidics and based in the cooperative laboratory with TBI3 hosted by INSA4 Toulouse. Alexandra Tauzin, Researcher in Enzyme Engineering and Microfluidics, and Alexandre Gilles, Engineer specialized in robotics, work in partnership with the Paul Pascal Research Center.

About Carbios

Established in 2011 by Truffle Capital, Carbios is a green chemistry company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recognized in April 2020 in a scientific paper published on the front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.

In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products. PVH Corp. joined this consortium in January 2023.

The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperature, integrating enzymes at the heart of the plastic product.

For more information, please visit www.carbios.com/en / Twitter: Carbios LinkedIn: Carbios Instagram: insidecarbios

Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.

Translation is for information purposes only.
In case of discrepancy between the French and the English version of this press release, the French version shall prevail

1 Centre de Recherche Paul Pascal (CRPP)
2 Centre National de la Recherche Scientifique (CNRS) = National Center for Scientific Research
3 Toulouse Biotechnology Institute
4 National Institute of Applied Sciences

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

CARBIOS
Melissa Flauraud
Press Relations
melissa.flauraud@carbios.com

Benjamin Audebert
Investor Relations
contact@carbios.com
+33 (0)4 73 86 51 76

Press Relations (Europe)
Iconic
Marie-Virginie Klein
mvk@iconic-conseil.com
+33 (0)1 44 14 99 96

Press Relations (U.S.)
Rooney Partners
Kate L. Barrette
kbarrette@rooneyco.com
+1 212 223 0561

Press Relations (DACH)
MC Services
Anne Hennecke
carbios@mc-services.eu
+49 (0)211 529 252 22

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CIG to Showcase How Next-Generation Broadband Is Driving More Value with PON, Wi-Fi, Optics, and Edge AI at Network X 2026, Booth C4.12.10.2026 10:11:00 EEST | Press release

Cambridge Industries Group (CIG), a global leader in broadband and optical connectivity technologies, will showcase its latest broadband, optical, and Edge AI platform innovation at Network X 2026, October 13-15 in Vienna. The exhibit will focus on a practical challenge for network operators: how to increase capacity while improving the experience. CIG’s broadband showcase will span the network from fiber access to the connected home. Visitors will see live demonstrations of Wi-Fi 8 capabilities in an XGS-PON gateway, previewing CIG’s approach to next-generation Wi-Fi: greater flexibility in platform design and more dependable performance in real-world subscriber environments. CIG will also demonstrate its prplWare 4.2.1-certified Wi-Fi 7 device. CIG will also showcase the AIU-100 Edge AI controller, initially focused on manufacturing applications. Designed to support local analysis of image, audio, and equipment sensor data, the platform provides a foundation for automated quality ins

Taxually Launches New E-Invoicing and Tax Calculation Products at Taxually Connect 202612.10.2026 10:00:00 EEST | Press release

Taxually, a leading global technology provider for indirect tax management, announced the launch of two new products for e-invoicing and tax calculation, together with new API capabilities, at Taxually Connect 2026. The full-day event, held on 29 September, brought together more than 100 finance, tax and technology leaders to discuss, debate and share views on where indirect tax compliance is heading in 2027 and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012937592/en/ Taxually CEO and Co-Founder Stefan Mladenovic talking about next wave of e-invoicing mandates arriving in 2026 and EU-wide digital reporting coming in 2030. Both new products are designed as seamless extensions of Taxually’s existing platform. They are differentiated by real-time accuracy embedded directly in clients’ systems, along with exceptionally smooth onboarding and integration. Taxually also presented its new API capabilities, which give

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo ® ) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 09:00:00 EEST | Press release

Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one of the largest real-world evaluations of mogamulizumab in Germany and add to the growing body of evidence supporting its use in routine clinical practice.1-3 Conducted as a company-sponsored, multicentric, non-interventional, combined retro-prospective real-world study across 18 centres throughout Germany, MINT brought together cutaneous T‑cell lymphoma (CTCL) specialists to evaluate treatment outcomes with mogamulizumab in a real-world setting, with time-to-next-treatment (TTNT) as the study’s primary endpoint.1 The study captured a broad and heterog

Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 09:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural next step for Megaport. “Portugal’s digital economy is rapidly growing, and infrastructure is at the heart of that transfor

Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 19:09:00 EEST | Press release

Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye